Physician profile
Daniel Feig
NPI 1942380290
$11,184.75
in general payments reported to CMS, 2019-2025
17 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Pediatric Nephrology provider received nationally (typical 2025 total: $131).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $4,159 · 2021: $5,148 · 2022: $1,536 · 2023: $14.84 · 2024: $75.04 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $342.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $5,173.38 | 2021-2025 | |
| Vifor Pharma, INC. | $3,950.00 | 2020 | |
| Sanofi Pasteur INC. | $1,448.00 | 2022 | |
| Apellis Pharmaceuticals, INC. | $190.14 | 2025 | Empaveli |
| Alexion Pharmaceuticals, INC. | $175.44 | 2020-2023 | Soliris |
| Azurity Pharmaceuticals, INC. | $62.40 | 2020-2025 | Katerzia |
| Mallinckrodt Hospital Products INC. | $31.47 | 2022 | |
| Ani Pharmaceuticals, INC. | $26.62 | 2024 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $23.30 | 2024 | |
| Recordati_rare_diseases_inc. | $20.91 | 2022 | |
| Eusa Pharma (US) LLC | $20.90 | 2022 | |
| Silvergate Pharmaceuticals, INC. | $18.87 | 2020 | |
| Baxter Healthcare | $17.52 | 2021 | |
| Cmp Pharma, INC. | $14.34 | 2022 | |
| Travere Therapeutics, INC. | $11.46 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Feig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.